Lamivudine Tablet, Film Coated
Product Images NDC 0904-6583

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 0904-6583). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

C445775a Cda8 453c Cbd4 016053ef4bb6 00

Packaging label for LAMIVUDINE 150 mg film-coated tablets, USP, by Major Pharmaceuticals. The label includes the proprietary name, dosage strength, unit dose indication, and instructions for pharmacists to dispense with patient information leaflet. It mentions prescription use only (Rx only) and the package contains 30 tablets. Additional details include storage conditions, usage warnings, and distributor information.*

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of lamivudine, showing the molecular arrangement including a sulfur-containing ring, hydroxyl group, and nitrogenous base typical of this antiviral medication.*

FDA Label Image

Figure1 (Figure1)

A line graph showing the proportions of patients with HIV-1 RNA less than 400 copies per mL over treatment time in weeks. The graph compares two dosing regimens of lamivudine: 150 mg twice daily and 300 mg once daily, with values plotted from 0 to 48 weeks.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.